Previous 10 | Next 10 |
2024-01-22 16:34:40 ET More on Adicet Bio Adicet Bio: Clinical Updates In H2 2024 Makes This A Must-Watch Adicet Bio stock rallies 26% on pipeline, cash runway updates Read the full article on Seeking Alpha For further details see: Adicet Bio stock sinks ...
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that it has commenced an underwritten public offering of its common stock and, in...
2024-01-09 19:36:03 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; NexImmune Inc (NASDAQ: NEXI), Adicet Bio Inc (NASDAQ: ACET), Cellectar Biosciences Stock (NASDAQ: CLRB), and Accolade (NASDAQ: ACCD). Other than ...
2024-01-09 12:43:25 ET Gainers: Neximmune NEXI +96% . Sentage Holdings SNTG +58% . Mountain Crest Acquisition Corp IV MCAF +48% . Zoomcar Holdings ZCAR +42% . Cutera CUTR +37% . Adicet Bio ( ACET ) +33% . Solid Biosciences ( SLDB ...
2024-01-09 12:40:00 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Cutera Inc (NASDAQ: CUTR), Sentage Holdings (NASDAQ: SNTG), NexImmune Inc (NASDAQ: NEXI), Adicet Bio In...
2024-01-08 19:19:55 ET Summary Clinical updates for its CAR-T programs ADI-001 for lupus nephritis and mantle cell lymphoma are expected in the second half of 2024. ADI-001 has shown promising results in late-line MCL patients, with high response rates and a good safety profile. ...
2024-01-04 12:34:16 ET More on Mid-day movers & Stocks. Relmada Therapeutics, Inc. (RLMD) Q3 2023 Earnings Call Transcript Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024 Avenue Therapeutics GAAP EPS of $0.06 beats by $0.32 ...
2024-01-04 12:00:28 ET More on Adicet Bio Seeking Alpha’s Quant Rating on Adicet Bio Historical earnings data for Adicet Bio Financial information for Adicet Bio For further details see: Adicet Bio stock rallies 26% on pipeline, cash runway updates
2024-01-04 10:00:14 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...
Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favora...
News, Short Squeeze, Breakout and More Instantly...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270 for the potentia...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potentia...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferi...